Suppr超能文献

胰岛素样生长因子指数和生物有效剂量对肢端肥大症立体定向放射外科治疗结果的影响:队列研究。

The Impact of Insulin-Like Growth Factor Index and Biologically Effective Dose on Outcomes After Stereotactic Radiosurgery for Acromegaly: Cohort Study.

机构信息

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.

Division of Endocrinology, Indiana University, Indianapolis, Indiana.

出版信息

Neurosurgery. 2020 Sep 1;87(3):538-546. doi: 10.1093/neuros/nyaa054.

Abstract

BACKGROUND

Stereotactic radiosurgery (SRS) is a safe and effective treatment for acromegaly.

OBJECTIVE

To improve understanding of clinical and dosimetric factors predicting biochemical remission.

METHODS

A single-institution cohort study of nonsyndromic, radiation-naïve patients with growth hormone-producing pituitary adenomas (GHA) having single-fraction SRS between 1990 and 2017. Exclusions were treatment with pituitary suppressive medications at the time of SRS, or <24 mo of follow-up. The primary outcome was biochemical remission-defined as normalization of insulin-like growth factor-1 index (IGF-1i) off suppression. Biochemical remission was assessed using Cox proportional hazards. Prior studies reporting IGF-1i were assessed via systematic literature review and meta-analysis using random-effect modeling.

RESULTS

A total of 102 patients met study criteria. Of these, 46 patients (45%) were female. The median age was 49 yr (interquartile range [IQR] = 37-59), and the median follow-up was 63 mo (IQR = 29-100). The median pre-SRS IGF-1i was 1.66 (IQR = 1.37-3.22). The median margin dose was 25 Gy (IQR = 21-25); the median estimated biologically effective dose (BED) was 169.49 Gy (IQR = 124.95-196.00). Biochemical remission was achieved in 58 patients (57%), whereas 22 patients (22%) had medication-controlled disease. Pre-SRS IGF-1i ≥ 2.25 was the strongest predictor of treatment failure, with an unadjusted hazard ratio (HR) of 0.51 (95% CI = 0.26-0.91, P = .02). Number of isocenters, margin dose, and BED predicted remission on univariate analysis, but after adjusting for sex and baseline IGF-1i, only BED remained significant-and was independently associated with outcome in continuous (HR = 1.01, 95% CI = 1.00-1.01, P = .02) and binary models (HR = 2.27, 95% CI = 1.39-5.22, P = .002). A total of 24 patients (29%) developed new post-SRS hypopituitarism. Pooled HR for biochemical remission given subthreshold IGF-1i was 2.25 (95% CI = 1.33-3.16, P < .0001).

CONCLUSION

IGF-1i is a reliable predictor of biochemical remission after SRS. BED appears to predict biochemical outcome more reliably than radiation dose, but confirmatory study is needed.

摘要

背景

立体定向放射外科(SRS)是治疗肢端肥大症的一种安全有效的治疗方法。

目的

提高对预测生化缓解的临床和剂量学因素的理解。

方法

对 1990 年至 2017 年间接受单次分割 SRS 的非综合征性、放射治疗初治生长激素分泌垂体腺瘤(GHA)的单机构队列研究。排除标准为 SRS 时使用垂体抑制药物治疗或随访时间<24 个月。主要结局是生化缓解定义为胰岛素样生长因子 1 指数(IGF-1i)抑制后正常化。采用 Cox 比例风险评估生化缓解。通过系统文献回顾和使用随机效应模型的荟萃分析评估先前报告 IGF-1i 的研究。

结果

共有 102 例患者符合研究标准。其中,46 例(45%)为女性。中位年龄为 49 岁(四分位距[IQR] = 37-59),中位随访时间为 63 个月(IQR = 29-100)。SRS 前 IGF-1i 的中位数为 1.66(IQR = 1.37-3.22)。中位边缘剂量为 25 Gy(IQR = 21-25);中位估计生物有效剂量(BED)为 169.49 Gy(IQR = 124.95-196.00)。58 例患者(57%)达到生化缓解,22 例患者(22%)疾病得到药物控制。SRS 前 IGF-1i≥2.25 是治疗失败的最强预测因素,未调整的风险比(HR)为 0.51(95%CI = 0.26-0.91,P = 0.02)。在单变量分析中,照射的等中心点数量、边缘剂量和 BED 预测缓解,但在调整性别和基线 IGF-1i 后,仅 BED 仍具有统计学意义-并且与连续(HR = 1.01,95%CI = 1.00-1.01,P = 0.02)和二进制模型(HR = 2.27,95%CI = 1.39-5.22,P = 0.002)的结果独立相关。共有 24 例患者(29%)在 SRS 后出现新的垂体功能减退症。IGF-1i 亚阈值时生化缓解的汇总 HR 为 2.25(95%CI = 1.33-3.16,P<0.0001)。

结论

IGF-1i 是 SRS 后生化缓解的可靠预测因子。BED 似乎比剂量更可靠地预测生化结果,但需要进一步的确认性研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67e/7426191/79cd58d2b17a/nyaa054ga.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验